In a report released today, Jason Kolbert from H.C. Wainwright initiated coverage with a Hold rating on IsoRay (NYSE: ISR) and a price target of $1. The company’s shares opened today at $0.58.
Kolbert said:
“Our therapeutic models are patient-based, reflecting our assumptions for the market size, and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model. For IsoRay we use a 15% discount rate as the company’s product (Cs-131 seeds) are approved for use in multiple indications. The two key risks we see for IsoRay are the quarterly revenues around the market dynamics in prostate cancer brachytherapy and the commercialization of GammaTile.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -5.1% and a 37.8% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IsoRay with a $2 average price target.
See today’s analyst top recommended stocks >>
Based on IsoRay’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.33 million. In comparison, last year the company had a GAAP net loss of $1.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IsoRay, Inc. is a medical technology company. Though its subsidiary IsoRay Medical, Inc., it develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases.
